ESG vs GLP-1RA vs ESG + GLP-1RA in Patients With Obesity, NAFLD and Advanced Fibrosis: A Randomized Controlled Trial

Conditions: Obesity; Liver Diseases; Liver Fibrosis; Liver Fat; NAFLD; Weight Loss; Insulin Resistance; Insulin Sensitivity; Insulin Sensitivity/Resistance; Metabolic Diseases; Diabetes; Diabetes Mellitus, Type 2; Diabetes Mellitus; NASH With Fibrosis; Non-Alcoholic Fatty Liver Disease; Non Alcoholic Fatty Liver; Non-alcoholic Steatohepatitis Interventions: Device: ESG; Drug: GLP1-RA Sponsors: Pichamol Jirapinyo, MD, MPH Not yet recruiting

https://clinicaltrials.gov/study/NCT06138821

Source: ClinicalTrials.gov - November 18, 2023 Category: Research Source Type: clinical trials